Pivotal Role of Serum IL-37 In Patients with Chronic HBV and HCV
DOI:
https://doi.org/10.23851/mjs.v34i3.1346Keywords:
IL-37, HBV, HCVAbstract
Interleukin-37 (IL-37) is an anti-inflammatory cytokine that has an intrinsic role in many diseases through its extracellular and intracellular mechanisms. It was found to be in high concentrations in chronic diseases. In this study, the concentration of IL-37 was measured in 62 patients with chronic hepatitis C and 65 patients with chronic hepatitis B with 38 individuals as Healthy group using ELISA to confirm that IL-37 can be used a biomarker for hepatitis chronic diseases. Receiver operating characteristic (ROC) curves were used to support this hypothesis. IL-37 levels were significantly higher in viral hepatitis patients (Hepatitis C virus and Hepatitis B virus) than in controls (92.28 ± 47.5, 83.1±43.44, 42.8±12.14 ng/L), respectively with p= 0.00001. The ROC curve showed that all hepatitis patients (HCV and HBV) could be distinguished from the control group according to their levels of IL-37 with an AUC value for HBV was 0.886, while for HCV was 0.955. In addition, the cut-off value for IL37 in patients suffer from HBV was 58.55 ng/L with a sensitivity of 80% and a specificity of 100 %, while the cut-off value for IL37 in HCV patients was 57.27 ng /L with a sensitivity of 90% and a specificity of 97%. This study concluded there was an increase in the IL-37 concentration in patients with chronic HBV and HCV.
Received: 14/03/2023
Revised: 05/05/2023
Accepted: 28/05/2023
Downloads
References
M. Carty, C.Guy, A.G. Bowie. Detection of viral infections by innate immunity. Biochemical pharmacology. 2021;1(183):pp114316.
M.Iannacone,F. Andreata, L.G. Guidotti. Immunological insights in the treatment of chronic hepatitis B. Current Opinion in Immunology. 2022; 1(77): pp102207.
L.Wang, Y.Quan, Y.Yue, X.Heng, F.Che. Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy. Oncology letters.2018 ;1 (4): pp4711-9.
S.Kumar, PC.McDonnell, R.Lehr, L .Tierney, MN.Tzimas, DE.Griswold, EA .Capper, R.Tal-Singer, GI.Wells, ML.Doyle, PR.Young. Identification and initial characterization of four novel members of the interleukin-1 family. Journal of Biological Chemistry.2000; 7;275(14): pp10308-14.
MF.Nold, CA.Nold-Petry, JA.Zepp, BE .Palmer, P.Bufler, CA.Dinarello. IL-37 is a fundamental inhibitor of innate immunity. Nature immunology.2010 ;11(11):pp1014-22.
Z.Su, X.Tao. Current understanding of IL-37 in human health and disease. Frontiers in Immunology.2021; 25(12): pp696605.
H.Zeng, K.Zhou, Z.Ye. Biology of interleukin 37 and its role in autoimmune diseases. Experimental and Therapeutic Medicine.2022; 1;24(2): pp1-0.
G.Allam, AM.Gaber, SI.Othman, A.Abdel-Moneim. The potential role of interleukin-37 in infectious diseases: role of IL-37 in HIV-1, viral myocarditis, HCV, HBV, tuberculosis, leprosy, pneumonia, listeria, aspergillosis, candidiasis, and eumycetoma infection. International reviews of immunology.2020; 2;39(1): pp3-10.
CA.Dinarello, C.Nold‐Petry, M.Nold, M .Fujita, S.Li, S.Kim, P.Bufler. Suppression of innate inflammation and immunity by interleukin‐37. European journal of immunology. 2016 ;46(5): pp1067-81.
SX.Ding, JB.Ma, YR.Hu, AR.Hu, Q.Shen, GS.Gao. Outcomes of interferon/ribavirin therapy in patients with HCV defined by expression of plasma soluble human leukocyte antigen-G but not IL-37. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2016; 22:pp1398.
G.Choudhuri, V.Gupta, TS.Negi, R.Ojha. Potential implications of detecting HBsAg in asymptomatic people in an endemic community through Medical Camps. Journal of Clinical and Experimental Hepatology. 2019 Jan 1;9(1):43-9.
G.Sebastiani, K.Gkouvatsos, K .Pantopoulos. Chronic hepatitis C and liver fibrosis. World journal of gastroenterology: WJG. 2014 Aug 8;20(32):11033.
Z.Ma, Q.Cao, Y.Xiong, E.Zhang, M.Lu. Interaction between hepatitis B virus and toll-like receptors: current status and potential therapeutic use for chronic hepatitis B. Vaccines. 2018 Jan 16;6(1):6.
C.Herrscher, P.Roingeard, E.Blanchard. Hepatitis B virus entry into cells. Cells. 2020 Jun 18;9(6):1486.
M.Hosel, M.Quasdorff, K.Wiegmann, D. Webb, U.Zedler, M.Broxtermann, R. Tedjokusumo, K.Esser, S.Arzberger, CJ .Kirschning, A.Langenkamp. Not interferon, but interleukin‐6 controls early gene expression in hepatitis B virus infection. Hepatology. 2009 Dec;50(6):1773-82.
AW.Thomson, PA.Knolle. Antigen-presenting cell function in the tolerogenic liver environment. Nature Reviews Immunology. 2010 Nov;10(11):753-66.
WH.Gerlich. Medical virology of hepatitis B: how it began and where we are now. Virology journal. 2013 Dec;10(1):1-25.
RA.Simmons, CB.Willberg, K.Paul. Immune evasion by viruses. eLS. 2013.
M.Kgatle,M.Setshedi.Immunopathogenesis of hepatitis B virus infection and related complications. EMJ Hepatol, 2016;4, pp.84-92.
Y.Chen, Z.Tian. HBV-induced immune imbalance in the development of HCC. Frontiers in Immunology. 2019 Aug 27;10:2048.
LB.Dustin, B.Bartolini, MR.Capobianchi, M.Pistello. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clinical microbiology and infection. 2016 Oct 1;22(10):826-32.
F.Streicher, N.Jouvenet. Stimulation of innate immunity by host and viral RNAs. Trends in Immunology. 2019 Dec 1;40(12):1134-48.
M.Lucas, P.Deshpande, I.James, A.Rauch, K.Pfafferott, E.Gaylard, S.Merani, A .Plauzolles, A.Lucas, W.McDonnell, S.Kalams. Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome. Scientific reports. 2018 May 8;8(1):7224.
UA.Ashfaq, T.Javed, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virology journal. 2011 Dec;8(1):1-0.
SF.Abdelwahab. Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?. Infectious agents and cancer. 2016 Dec;11(1):1-2.
E.Shin, C.Sung, S. H.,. Park, Immune responses and immunopathology in acute and chronic viral hepatitis. Nature Reviews Immunology. 2016;16(8), 509.
M.B.Zeisel, J.Lupberger, I.Fofana, and T.F.Baumert, , Host-targeting agents for prevention and treatment of chronic hepatitis C-perspectives and challenges. Journal of hepatology. 2013;58(2), pp.375-384.
Q.He, Q.He, X.Qin, S.Li, T.Li, L.Xie, et al., The relationship between inflammatory marker levels and hepatitis C virus severity. Gastroenterology Research and Practice.2016;2016.
M. Lucas, P.Deshpande, I.James, A.Rauch, K.Pfafferott, E.Gaylard, et al., Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome. Scientific reports. 2018;8(1), pp.1-10.
Q.Ding, X.Cao, J.Lu, B.Huang, J.Y.Liu, N.Kato, et al., Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. Journal of hepatology.2013;.59(1), pp.52-58.
NS.Gokhale, C.Vazquez, SM.Horner, Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol. 2014.;9(12).
H.Kared, T.Fabre, N.Bedard, , J.Bruneau, and N.H.Shoukry. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS pathogens.2013;9(6), p.e1003422.
S.Tete, D.Tripodi, M.Rosati, F.Conti, G. Maccauro, A.Saggini, E.Cianchetti, A.Caraffa, P.Antinolfi, E.Toniato, ML.Castellani. IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. International journal of immunopathology and pharmacology. 2012 ;25(1):31-38.
A.M.Ellisdon, C.A.Nold-Petry, L.D'Andrea, S.X.Cho, J.C.Lao, I.Rudloff, D.Ngo, C.Y.Lo , T.P.Soares da Costa, M.A.Perugini, and P.J.Conroy, , Homodimerization attenuates the anti-inflammatory activity of interleukin-37. Science immunology. 2017;2(8), p.eaaj1548.
C.Li, H.Ji, Y.Cai, DA.Ayana, P.Lv, M. Liu, Y.Jiang. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. Journal of Interferon & Cytokine Research.2013; 1,33(10): pp612-618.
Meng JP, Luo P, Bai Y, Cui F. Entecavir downregulates interleukin-37 in patients with chronic active hepatitis B infection. Journal of International Medical Research. 2020 Jan;48(1):0300060519884157.
Q.Liu, Q.Zhou, M.Wang, B.Pang. Interleukin-37 suppresses the cytotoxicity of hepatitis B virus peptides-induced CD8+ T cells in patients with acute hepatitis B. Biomolecules and Biomedicine.2023;1:pp1-9.
H.Jia, J.Liu, B.Han. Reviews of interleukin-37: functions, receptors, and roles in diseases. BioMed Research International.2018;1(4).
EZ.Eisenmesser, A.Gottschlich, JS .Redzic, N.Paukovich, JC.Nix, T.Azam, L. Zhang, R.Zhao, JS.Kieft, E.The, X.Meng. Interleukin-37 monomer is the active form for reducing innate immunity. Proceedings of the National Academy of Sciences. 2019; 116(12): pp5514-22.
Downloads
Key Dates
Published
Issue
Section
License
Copyright (c) 2023 Al-Mustansiriyah Journal of Science
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
(Starting May 5, 2024) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
How to Cite
